Group 1 - The company, Baillie Gifford, plans to globally offer 8.6343 million shares, with 863,500 shares available in Hong Kong and 7.7708 million shares for international sale [1] - The subscription period is set from November 7 to November 12, with a maximum offer price of HKD 389.00 per share, and the entry fee is approximately HKD 39,292.31 for 100 shares [1] - The total expected fundraising amount is HKD 3.18 billion, with a net amount of HKD 3.018 billion, intended for research and development of biological drug candidates outside mainland China, establishing a global supply chain, and general corporate purposes [1] Group 2 - The company has introduced cornerstone investors including Bristol-Myers Squibb, OAP III (HK) Limited, GL China Long Equity Opportunities SPV L.P., Athos Capital Limited, and Franklin Templeton Investments, who will subscribe to approximately 638,900 shares at the offer price [1] - The company is expected to be listed on the main board on November 17, 2025, with joint sponsors including Goldman Sachs (Asia) LLC, J.P. Morgan Securities (Far East) Limited, and CITIC Securities (Hong Kong) Limited [1] Group 3 - The company's main business includes wholesale of biochemical drugs, biological products (excluding preventive biological products), chemical raw materials, antibiotic raw materials, traditional Chinese medicine, chemical drug formulations, and antibiotic formulations [2] - The net profits for the years 2023, 2024, and the first half of 2025 (ending June 30) are projected to be -780 million, 3.708 billion, and -1.118 billion respectively, with year-on-year changes of -176.40%, 575.02%, and -123.96% [2]